168 related articles for article (PubMed ID: 30846404)
1. Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
Xu JF; Wang TT; Yuan Q; Duan YT; Xu YJ; Lv PC; Wang XM; Yang YS; Zhu HL
Bioorg Med Chem; 2019 Apr; 27(8):1509-1516. PubMed ID: 30846404
[TBL] [Abstract][Full Text] [Related]
2. Introducing Broadened Antibacterial Activity to Rhodanine Derivatives Targeting Enoyl-Acyl Carrier Protein Reductase.
Sun ZG; Xu YJ; Xu JF; Liu QX; Yang YS; Zhu HL
Chem Pharm Bull (Tokyo); 2019; 67(2):125-129. PubMed ID: 30713272
[TBL] [Abstract][Full Text] [Related]
3. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
[TBL] [Abstract][Full Text] [Related]
4. In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA.
Slepikas L; Chiriano G; Perozzo R; Tardy S; Kranjc A; Patthey-Vuadens O; Ouertatani-Sakouhi H; Kicka S; Harrison CF; Scrignari T; Perron K; Hilbi H; Soldati T; Cosson P; Tarasevicius E; Scapozza L
J Med Chem; 2016 Dec; 59(24):10917-10928. PubMed ID: 26730986
[TBL] [Abstract][Full Text] [Related]
5. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel N-methyl carbazole tethered rhodanine derivatives as direct inhibitors of Mycobacterium tuberculosis InhA.
Shaikh MS; Kanhed AM; Chandrasekaran B; Palkar MB; Agrawal N; Lherbet C; Hampannavar GA; Karpoormath R
Bioorg Med Chem Lett; 2019 Aug; 29(16):2338-2344. PubMed ID: 31227345
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
8. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
10. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
[TBL] [Abstract][Full Text] [Related]
11. First triclosan-based macrocyclic inhibitors of InhA enzyme.
Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
[TBL] [Abstract][Full Text] [Related]
12. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
[TBL] [Abstract][Full Text] [Related]
14. Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme.
Venugopala KN; Chandrashekharappa S; Deb PK; Tratrat C; Pillay M; Chopra D; Al-Shar'i NA; Hourani W; Dahabiyeh LA; Borah P; Nagdeve RD; Nayak SK; Padmashali B; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Haroun M; Shashikanth S; Mohanlall V; Mailavaram R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1472-1487. PubMed ID: 34210233
[TBL] [Abstract][Full Text] [Related]
15. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, SAR and biological investigation of 3-(carboxymethyl)rhodanine and aminothiazole inhibitors of Mycobacterium tuberculosis Zmp1.
Mori M; Deodato D; Kasula M; Ferraris DM; Sanna A; De Logu A; Rizzi M; Botta M
Bioorg Med Chem Lett; 2018 Feb; 28(4):637-641. PubMed ID: 29395975
[TBL] [Abstract][Full Text] [Related]
17. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
Parikh SL; Xiao G; Tonge PJ
Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
[TBL] [Abstract][Full Text] [Related]
19. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
[TBL] [Abstract][Full Text] [Related]
20. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
